Concord Drugs Intrinsic Value
CONCORD Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹24.92 | ₹19.94 - ₹29.90 | -70.0% | EPS: ₹0.76, Sector P/E: 22x |
| Book Value Method | asset | ₹68.00 | ₹61.20 - ₹74.80 | -18.1% | Book Value/Share: ₹34.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹80.00 | ₹72.00 - ₹88.00 | -3.7% | Revenue/Share: ₹40.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹39.65 | ₹35.69 - ₹43.62 | -52.3% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹54.33 | ₹43.46 - ₹65.20 | -34.6% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹24.92 | ₹22.43 - ₹27.41 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹24.92 | ₹22.43 - ₹27.41 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹24.92 | ₹22.43 - ₹27.41 | -70.0% | EPS: ₹0.76, BVPS: ₹34.00 |
Want to compare with current market value? Check CONCORD share price latest .
Valuation Comparison Chart
CONCORD Intrinsic Value Analysis
What is the intrinsic value of CONCORD?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Concord Drugs (CONCORD) is ₹39.65 (median value). With the current market price of ₹83.06, this represents a -52.3% variance from our estimated fair value.
The valuation range spans from ₹24.92 to ₹80.00, indicating ₹24.92 - ₹80.00.
Is CONCORD undervalued or overvalued?
Based on our multi-method analysis, Concord Drugs (CONCORD) appears to be trading above calculated value by approximately 52.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 8.20 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.91 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.62x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Concord Drugs
Additional stock information and data for CONCORD
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |